OptimizeRx Signs Exclusive Agreement with NewCrop to Offer Digital Health Messages and Create a Health Tech Innovation Lab for Life Sciences
The agreement builds upon a long standing, profitable relationship between the two partners, and solidifies
“We’ve seen tremendous success through our previous programs with NewCrop,” noted
“We’re excited to build on this baseline by honing our combined focus through exclusivity, and include NewCrop as our founding partner in the launch of the
For NewCrop, the partnership means broader distribution of medication-specific information delivered conveniently within their healthcare providers daily workflow.
According to
“The Innovation Lab will help us bring new ideas to life more quickly. By combining our access to physicians with the
Both the
“We’re firm believers in the ‘power of connection,’” added Paramore. “The formation of
About NewCrop
NewCrop is the leading electronic prescribing service and has been deployed in a wide range of EHRs and medical networks since 2003. The company’s user interface allows for rapid installation of fully expedited e-Prescription networking, as well as real-time benefits, PDMP, pharmacogenomic decision support, DEA-compliant EPCS and more. All services are HITRUST certified and available as an integrated user interface and/or customizable widgets, facilitating easy and flexible installations to fast track network and ONC certifications. For more information, visit www.newcroprx.com.
About
The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information.
For more information, follow the company on Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.
OptimizeRx Contact
Tel (248) 651-6568 x807
dbaker@optimizerx.com
Media Relations Contact
Tel (860) 800-2344
oprx@innsena.com
Investor Relations Contact
Tel (949) 432-7557
oprx@cma.team
Source: OptimizeRx Corporation